Jacobs Levy Equity Management’s Prelude Therapeutics PRLD Stock Holding History

Jacobs Levy Equity Management’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-666,574	Closed	-$850K	–	1173
2024 Q4	$850K	Buy	666,574 +491,595	+281%	+$652K	﹤0.01%	737
2024 Q3	$362K	Buy	174,979 +157,218	+885%	+$728K	﹤0.01%	866
2024 Q2	$67.7K	Buy	+17,761	New	+$72.3K	﹤0.01%	937
2024 Q1	–	Sell	-131,307	Closed	-$561K	–	1030
2023 Q4	$561K	Sell	131,307 -12,650	-9%	-$38.5K	﹤0.01%	813
2023 Q3	$445K	Buy	143,957 +27,470	+24%	+$103K	﹤0.01%	827
2023 Q2	$524K	Buy	116,487 +31,820	+38%	+$190K	﹤0.01%	817
2023 Q1	$483K	Buy	+84,667	New	+$516K	﹤0.01%	808
2022 Q1	–	Sell	-130,280	Closed	-$1.62M	–	1070
2021 Q4	$1.62M	Buy	+130,280	New	+$2.12M	0.01%	661

Other funds holding PRLD

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management's PRLD Position: Q1 2025 in Review

Jacobs Levy Equity Management sold out of Prelude Therapeutics (PRLD) in Q1 2025, closing a stake of 666,574 shares — an estimated $850K sold.

Jacobs Levy Equity Management first reported a position in PRLD in Q4 2021 and held it in 8 quarters. The position peaked at $1.62M in Q4 2021. 59 funds tracked by Wall St. Rank hold PRLD as of Q1 2025.

Jacobs Levy Equity Management reported no remaining Prelude Therapeutics position as of Q1 2025 after selling out during the quarter.
Jacobs Levy Equity Management sold 666,574 Prelude Therapeutics shares in Q1 2025, an estimated $850K.
Jacobs Levy Equity Management first reported a position in Prelude Therapeutics in Q4 2021 and held it in 8 quarters.
Jacobs Levy Equity Management's Prelude Therapeutics position peaked at $1.62M in Q4 2021.
59 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2025, filed 15 May 2025.